Cargando…

Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients

Model-based meta-analysis of dose response is a sophisticated method to guide dose and regimen selection. In this report, the effects of paclitaxel dose and regimen (weekly or every 3 weeks) on the efficacy and safety in cancer patients were quantified by model-based meta-analysis of 29 monotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, D, Joshi, A, Li, H, Zhang, N, Ren, M M, Gao, Y, Wada, R, Jin, J Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055787/ https://www.ncbi.nlm.nih.gov/pubmed/24850445 http://dx.doi.org/10.1038/psp.2014.14

Ejemplares similares

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
por: Lu, Jian-Feng, et al.
Publicado: (2012)

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
por: Shitara, K, et al.
Publicado: (2014)

A dose response model for quantifying the infection risk of antibiotic-resistant bacteria
por: Chandrasekaran, Srikiran, et al.
Publicado: (2019)

Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach
por: Benguigui, Madeleine, et al.
Publicado: (2017)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Quantifying the Collision Dose in Rugby League: A Systematic Review, Meta-analysis, and Critical Analysis
por: Naughton, Mitchell, et al.
Publicado: (2020)

Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis
por: Li, Bingxue, et al.
Publicado: (2021)

Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs
por: Axiak, Sandra M, et al.
Publicado: (2011)

Correction to: Quantifying the Collision Dose in Rugby League: A Systematic Review, Meta-analysis, and Critical Analysis
por: Naughton, Mitchell, et al.
Publicado: (2020)

Validated HPLC Method for the Determination of Paclitaxel-related Substances in an Intravenous Emulsion Loaded with a Paclitaxel–Cholesterol Complex
por: Xia, X. J., et al.
Publicado: (2013)

Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis
por: Li, Bing-Xue, et al.
Publicado: (2021)

Nanoparticle Albumin‑Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
por: Gangannapalle, Mahesh, et al.
Publicado: (2023)

Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction
por: Sundqvist, M, et al.
Publicado: (2015)

The Efficacy and Toxicity of Paclitaxel Plus S-1 Compared With Paclitaxel Plus 5-Fu for Advanced Gastric Cancer: A PRISMA Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Liu, Huan, et al.
Publicado: (2014)

Low-dose paclitaxel modulates tumour fibrosis in gastric cancer
por: TSUKADA, TOMOYA, et al.
Publicado: (2013)

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
por: Vaz-Luis, Ines, et al.
Publicado: (2020)

Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis
por: Hao, Wenjing, et al.
Publicado: (2023)

Alcohol, coffee and tea intake and the risk of cognitive deficits: a dose–response meta-analysis
por: Ran, L. S., et al.
Publicado: (2021)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

Leveraging Mathematical Modeling to Quantify Pharmacokinetic and Pharmacodynamic Pathways: Equivalent Dose Metric
por: McKenna, Matthew T., et al.
Publicado: (2019)

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
por: Koizumi, Wasaburo, et al.
Publicado: (2015)

Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression
por: Saggam, Akash, et al.
Publicado: (2022)

A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel
por: França, Fábio, et al.
Publicado: (2020)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
por: Gong, Wenjian, et al.
Publicado: (2023)

Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192
por: Sun, Lin, et al.
Publicado: (2011)

Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
por: Ma, Yuan, et al.
Publicado: (2021)

Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study
por: Imai, Natsuko, et al.
Publicado: (2023)

Meta-Analysis of Paclitaxel-Based Chemotherapy Combined With Traditional Chinese Medicines for Gastric Cancer Treatment
por: Li, Yicong, et al.
Publicado: (2020)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

The dose–response characteristics of four NTCP models: using a novel CT-based radiomic method to quantify radiation-induced lung density changes
por: Begosh-Mayne, Dustin, et al.
Publicado: (2020)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
por: Hirst, Jennifer A., et al.
Publicado: (2012)

Concept for quantifying the dose from image guided radiotherapy
por: Schneider, Uwe, et al.
Publicado: (2015)

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
por: Somlo, G, et al.
Publicado: (2001)

Prodrug Strategies for Paclitaxel
por: Meng, Ziyuan, et al.
Publicado: (2016)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Quantifying uncertainty, variability and likelihood for ordinary differential equation models
por: Weiße, Andrea Y, et al.
Publicado: (2010)

A Generalized Measurement Model to Quantify Health: The Multi-Attribute Preference Response Model
por: Krabbe, Paul F. M.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_acbhfd2ugavj7oi97u3tmhqrgh